Brazil to become world supplier of Chagas disease treatment

NewsGuard 100/100 Score

"Brazil is keen to take part in the international effort to expand access to medicines and to produce its own drugs, and will start by becoming the world supplier of medicines to treat Chagas disease," Health Minister Alexandre Padilha announced "at the World Conference on Social Determinants of Health, which opened Tuesday October 19 in Rio de Janeiro," Inter Press Service reports. "Production of benznidazole, the drug in question, will reach 3.4 million tablets by the end of this year," the news service writes.

The South American country "'will take on the commitment of guaranteeing worldwide production of medicines for Chagas disease,' ... the health minister said," IPS notes, adding, "Brazil already manufactures 1.2 million tablets a year of the medicine, according to estimates by the Pan American Health Organization (PAHO)." According to IPS, "In 2008, Brazil became the world's only producer of the medicine, when the state LAFEPE laboratory in the northeastern state of Pernambuco purchased stocks of ingredients from Swiss pharmaceutical company Roche, which ceased to manufacture it" (10/20).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning paves the way for precision medicine in UTI treatments